T. Rowe Price Associates
IPSC icon

T. Rowe Price Associates’s Century Therapeutics IPSC Stock Holding History

T. Rowe Price Associates’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+101,164
New +$231K ﹤0.01% 2929
2025
Q2 		– Sell
-14,882
Closed -$8K – 3100
2025
Q1 		$8K Hold
14,882
– – ﹤0.01% 3026
2024
Q4 		$16K Hold
14,882
– – ﹤0.01% 2998
2024
Q3 		$26K Hold
14,882
– – ﹤0.01% 2976
2024
Q2 		$38K Buy
+14,882
New +$47K ﹤0.01% 2882

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

T. Rowe Price Associates's IPSC Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Century Therapeutics (IPSC) in Q2 2026: 101,164 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #2929 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in IPSC as recently as Q1 2025.

T. Rowe Price Associates first reported a position in IPSC in Q2 2024 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • T. Rowe Price Associates held 101,164 shares of Century Therapeutics worth $248K as of Q2 2026.
  • Century Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2929 holding.
  • T. Rowe Price Associates first reported a position in Century Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.